Hugel Inc.August 20, 2021

FDA 483 - Hugel Inc. - August 20, 2021

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hugel Inc.

Record Details

Hugel, Inc. in Chuncheon, Gangwon, Korea, was inspected for drug substance and drug product manufacturing. The inspection revealed significant issues related to Clostridium botulinum spore control, including inadequate containment, decontamination, and environmental monitoring. Additionally, the firm had deficiencies in OOS investigations, logbook management, cell bank comparability, and batch filling time controls.

Company: Hugel Inc.
Inspection Date: August 20, 2021
Product Type: Drugs
Office: Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)
People: Mekonnen Lemma Dechassa
Madushini N. Dharmasena

Open in Dashboard

ID · 21fcd217-7913-4979-9020-de9e0f5af888